Caesarea, Israel – October 13, 2026 -- IceCure Medical (Nasdaq: ICCM) reported 12-month objective response rates of 97.5% among 40 breast cancer patients treated with ProSense® cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands.